Substitute for form 1449/PTO				Complete if Known			
				Application Number	10/664,803		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	September 19, 2003		
				First Named Inventor	Kositprapa et al.		
				Art Unit	1615		
				Examiner Name	Sasan, Aradhana		
Sheet	1	of	1	Attorney Docket Number	141-424		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title	
	EA	An English translation of an opposition filed in Columbia against a related foreign application.	
	EB	A response to the opposition filed in Columbia against a related foreign application (in Spanish).	
	EC	An English translation of a response to the opposition filed in Columbia against a related foreign application.	
	ED	A search report from the Georgian Patent Office (and English translation).	
	EE	An Office Action from the Ukrainian Patent Office (and English translation).	
	EF	Efficacy of Metabolic Effects of Metformin and Troglitazone in type II diabetes mellitus; INZUCCHI SE et al. N. Engl. J Med. 1998 Mar 26; 338(13): 867-72.	
	EG	Effect of Metformin and Rosiglitazone combination therapy in patients with type II diabetes mellitus, FONSECA V, et al.; 2000 Apr 5; 283(13): 1695-702.	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.